Holowesko Partners Ltd. Gilead Sciences, Inc. Transaction History

Holowesko Partners Ltd.

9 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2021 May 13, 2021	SELL	$60.0 - $68.46 $2.94 Million - $3.35 Million	-49,000 Closed	0 $0
Q2 2020 Aug 12, 2020	SELL	$72.34 - $84.0 $11.5 Million - $13.4 Million	-159,000 Reduced 76.44%	49,000 $3.77 Million
Q1 2020 May 13, 2020	SELL	$62.63 - $80.22 $56.9 Million - $72.9 Million	-909,000 Reduced 81.38%	208,000 $15.6 Million
Q3 2019 Nov 12, 2019	SELL	$62.51 - $69.0 $1.25 Million - $1.38 Million	-20,000 Reduced 1.76%	1,117,000 $70.8 Million
Q2 2019 Aug 12, 2019	BUY	$61.87 - $69.38 $70.3 Million - $78.9 Million	1,137,000 New	1,137,000 $76.8 Million
Q3 2018 Nov 13, 2018	SELL	$71.28 - $78.92 $65.6 Million - $72.6 Million	-920,000 Closed	0 $0
Q2 2018 Aug 10, 2018	SELL	$64.88 - $75.68 $1.95 Million - $2.27 Million	-30,000 Reduced 3.16%	920,000 $65.2 Million
Q1 2018 May 14, 2018	SELL	$72.84 - $88.8 $19.5 Million - $23.8 Million	-268,000 Reduced 22.0%	950,000 $71.6 Million
Q3 2017 Nov 13, 2017	BUY	$72.11 - $85.47 $87.8 Million - $104 Million	1,218,000	1,218,000 $98.7 Million

1,927

994M

10.5M

9.75M

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

Get notified when there are updates to the investment portfolio of Holowesko Partners Ltd., based on Form 13F filings with the SEC.

Stay updated on Holowesko Partners Ltd. with notifications on news.